Insider Selling: CG Oncology (NASDAQ:CGON) Director Sells $74,540.00 in Stock

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $74.54, for a total value of $74,540.00. Following the transaction, the director directly owned 1,000 shares in the company, valued at approximately $74,540. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

CG Oncology Trading Down 3.8%

Shares of NASDAQ CGON opened at $77.61 on Friday. CG Oncology, Inc. has a 12 month low of $24.85 and a 12 month high of $80.97. The stock has a 50 day moving average of $70.91 and a 200-day moving average of $65.44. The company has a market capitalization of $6.88 billion, a P/E ratio of -28.85 and a beta of 0.23.

CG Oncology (NASDAQ:CGON) last posted its earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.24). CG Oncology had a negative return on equity of 25.20% and a negative net margin of 3,602.68%.The business had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.36 million. Analysts predict that CG Oncology, Inc. will post -3.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on CGON shares. Piper Sandler increased their price objective on shares of CG Oncology from $82.00 to $85.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. JPMorgan Chase & Co. lifted their target price on shares of CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Royal Bank Of Canada lowered their price target on shares of CG Oncology from $81.00 to $79.00 and set an “outperform” rating on the stock in a report on Friday, August 7th. Wolfe Research started coverage on shares of CG Oncology in a research report on Tuesday, May 19th. They set a “peer perform” rating for the company. Finally, Truist Financial upped their target price on CG Oncology from $82.00 to $85.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $83.18.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Whittier Trust Co. of Nevada Inc. bought a new position in shares of CG Oncology in the 4th quarter valued at $27,000. Fiduciary Financial Advisors bought a new stake in CG Oncology during the 2nd quarter worth $28,000. NFSG Corp bought a new stake in CG Oncology during the 1st quarter worth $34,000. Comerica Bank increased its holdings in CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after purchasing an additional 515 shares in the last quarter. Finally, Fifth Third Bancorp bought a new position in CG Oncology in the first quarter valued at about $74,000. Institutional investors and hedge funds own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.